The Concept of CMR

References

1. Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 1867-72.
2. Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-9.
3. Abate N and Garg A. Heterogeneity in adipose tissue metabolism: causes, implications and management of regional adiposity. Prog Lipid Res 1995; 34: 53-70.
4. Darvall KA, Sam RC, Silverman SH, et al. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007; 33: 223-33.
5. Juhan-Vague I, Alessi MC and Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-62.
6. Flier JS. The adipocyte: storage depot or node on the energy information superhighway? Cell 1995; 80: 15-8.
7. Kershaw EE and Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-56.
8. Loskutoff DJ and Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18: 1-6.
9. Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
10. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-3.
11. Vague P, Juhan-Vague I, Aillaud MF, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-3.
12. Juhan-Vague I, Alessi MC, Mavri A, et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-9.
13. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907.
14. Vague P, Juhan-Vague I, Chabert V, et al. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 1989; 38: 913-5.
15. Cigolini M, Targher G, Bergamo Andreis IA, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 368-74.
16. Janand-Delenne B, Chagnaud C, Raccah D, et al. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998; 22: 312-7.
17. Kruszynska YT, Yu JG, Olefsky JM, et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633-9.
18. Mertens I, Verrijken A, Michiels JJ, et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30: 1308-14.
19. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-8.
20. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13: 51-9.
21. Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 426-9.
22. Konstantinides S, Schafer K, Koschnick S, et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-40.
23. Reiner AP, Siscovick DS and Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 584-95.
24. Juhan-Vague I, Morange P, Renucci JF, et al. Fibrinogen, obesity and insulin resistance. Blood Coagul Fibrinolysis 1999; 10 Suppl 1: S25-8.
25. Folsom AR, Qamhieh HT, Wing RR, et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 162-9.
26. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-8.
27. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-9.
28. Sonnenberg GE, Krakower GR and Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004; 12: 180-6.
29. Woods A, Brull DJ, Humphries SE, et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21: 1574-83.
30. Block G, Dietrich M, Norkus EP, et al. Factors associated with oxidative stress in human populations. Am J Epidemiol 2002; 156: 274-85.
31. Loscalzo J. Oxidant stress: a key determinant of atherothrombosis. Biochem Soc Trans 2003; 31: 1059-61.
32. Davi G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. Jama 2002; 288: 2008-14.
33. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003; 11: 1278-89.